Genentech: Tim Wilson | Senior Scientist, Oncology Biomarker Development

A link to this page has been copied to your clipboard.

http://www.gene.com/scientists/our-scientists/tim-wilson

Paste this link in an email to share.

Ok

Print

Scientists / Our Scientists

"It is very exciting to be a contributor to cross-functional, multifaceted teams with the same goal in mind – to bring the best anti-cancer medicines to patients that need them the most."

9

Years at Genentech

18

Publications

I joined the Oncology Biomarker Development group at Genentech in 2011, following my postdoctoral research at Massachusetts General Hospital / Harvard Medical School. I was attracted to Genentech as I had a passion to translate pre-clinical research into therapies for biomarker-defined patient populations.

Predictive biomarkers are critical to the vision of precision medicine. My role at Genentech is to develop and test biomarker hypotheses to enable clinical development of experimental medicines in the most appropriate patient populations.

Featured Publication

The Molecular Landscape of High-Risk Early Breast Cancer: Comprehensive Biomarker Analysis of a Phase III Adjuvant Population

npj Breast Cancer 2, Article number: 16022 (2016), doi:10.1038/npjbcancer.2016.22

Timothy R. Wilson, Jianjun Yu, Xuyang Lu, Jill M. Spoerke, Yuanyuan Xiao, Carol O’Brien, Heidi Savage, Ling-Yuh Huw, Wei Zou, Hartmut Koeppen, William F. Forrest, Jane Fridlyand, Ling Fu, Rachel Tam, Erica B. Schleifman, Teiko Sumiyoshi, Luciana Molinero, Garret M. Hampton, Joyce A. O’Shaughnessy and Mark R. Lackner

My group focuses on two main areas: (1) to develop and implement robust biomarker strategies that enable clinical development of experimental therapeutics; and (2) to decipher the biomarker landscape of breast cancer to study biomarker prevalence and overlap, as well as to determine any prognostic implications associated with key patient subsets.

Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer

Journal of Clinical Oncology, ISSN: 15277755

Peter Schmid; Sarah Pinder; Duncan Wheatley; Jane Macaskill; Charles Zammit; Jennifer Hu; Robert Price; Nigel Bundred; Sirwan Hadad; Alice Shia; Shah-Jalal Sarker; Louise Lim; Patrycja Gazinska; Natalie Woodman; Darren Korbie; Matt Trau; Paul Mainwaring; Steven Gendreau; Mark Lackner; Mika Derynck; Tim Wilson; Hannah Butler; Gemma Earl; Parker; Arnie Purushotham; Alastair Thompson

Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer

Annals of Oncology, ISSN: 15698041

Diéras; Campone; Denise A. Yardley; Romieu; Vicente Valero; Isakoff; Hartmut Koeppen; Tim Wilson; Xiao; David Shames; Simonetta Mocci; Chen; Schmid

The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation

Cancer Research, ISSN: 15387445

Debasish Raha; Tim Wilson; Jing Peng; David Peterson; Peng Yue; Marie Evangelista; Catherine Wilson; Mark Merchant; Jeffrey Settleman

Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers

PLoS ONE, ISSN: 19326203

Erica Schleifman; Rupal Desai; Jill Spoerke; Yuanyuan Xiao; Cheryl Wong; Ilma Abbas; Carol O'Brien; Rajesh Patel; Teiko Sumiyoshi; Ling Fu; Nga Wan Rachel Tam; Hartmut Koeppen; Tim Wilson; Rajiv Raja; Garret Hampton; Mark Lackner

Amphiregulin and pten evoke a multimodal mechanism of acquired resistance to PI3k inhibition

Genes and Cancer, ISSN: 19476027

Kyle Edgar; Lisa Crocker; Eric Cheng; Marie-Claire Wagle; Matthew Wongchenko; Yibing Yan; Tim Wilson; Nick Dompe; Rich Neve; Marcia Belvin; Deepak Sampath; Lori Friedman; Jeffrey Wallin

Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer

Breast Cancer Research and Treatment, ISSN: 15737217

Arthur; Turnbull; Renshaw; Keys; Thomas; Tim Wilson; Mark Lackner; Sims; Dixon

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples

Breast Cancer Research and Treatment, ISSN: 15737217

Tim Wilson; Yuanyuan Xiao; Jill Spoerke; Jane (Zhenya) Fridlyand; Hartmut Koeppen; Eloisa Fuentes; Ling-Yuh Huw; Ilma Abbas; Arjan Gower; Erica Schleifman; Rupal Desai; Ling Fu; Teiko Sumiyoshi; Joyce A. O’Shaughnessy; Garret Hampton; Mark Lackner

High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck

PLoS ONE, ISSN: 19326203

David Shames; Juliet Carbon; Kimberly Walter; Adrian Jubb; Cleopatra Kozlowski; Tom Januario; An Do; Ling Fu; Yuanyuan Xiao; Rajiv Raja; Brittany Jiang; Ashi Malekafzali; Howard Stern; Jeffrey Settleman; Tim Wilson; Garret Hampton; Bob Yauch; Andrea Pirzkall; Lukas Amler

Mechanisms of acquired resistance to targeted cancer therapies

Future Oncology, ISSN: 17448301

Mark Lackner; Tim Wilson; Jeffrey Settleman

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Nature, ISSN: 00280836

Tim Wilson; Jane (Zhenya) Fridlyand; Yibing Yan; Elicia Penuel; Luciana Burton; Emily Chan; Jing Peng; Eva Lin; Yulei Wang; Jeffrey A. Sosman; Antoni Ribas; Jiang Li; John Moffat; Dan Sutherlin; Hartmut Koeppen; Mark Merchant; Rich Neve; Jeffrey Settleman

EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling

Growth Factors, ISSN: 08977194

Kristy J. Wilson; Christopher Mill; Sydney Lambert; Jennifer Buchman; Tim Wilson; Victor Hernandez-Gordillo; Richard M. Gallo; Laura M.C. Ades; Jeffrey Settleman; David J. Riese II

Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers

Cancer Cell, ISSN: 15356108

Tim Wilson; Diana Y. Lee; Leanne Ross; David Shames; Jeffrey Settleman

Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors

Cancer Discovery, ISSN: 21598290

Dejan Juric; Ian E. Krop; Ramesh K. Ramanathan; Tim Wilson; Joseph Ware; Sandra Sanabria; Heidi M. Savage; Deepak Sampath; Laurent Salphati; Ray Lin; Huan Jin; Hema Parmar; Jerry Y. Hsu; Daniel D. Von Hoff; Baselga

Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers

Annals of Oncology, ISSN: 15698041

Fumagalli; Tim Wilson; Roberto Salgado; Lu; Yu; Carol O'Brien; Kimberly Walter; Ling-Yuh Huw; Carmen Criscitiello; Laios; Jose; Brown; Rothé; Maetens; Zardavas; Peter Savas; Denis Larsimont; Piccart-Gebhart; Stefan Michiels; Mark Lackner; Christos Sotiriou; Sherene Loi

The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation

Cancer Research, ISSN: 15387445 00085472

Debasish Raha; Tim Wilson; Jing Peng; David Peterson; Peng Yue; Marie Evangelista; Catherine Wilson; Mark Merchant; Jeffrey E. Settleman

Phase II study of Taselisib (GDC-0032) in combination with fulvestrant in patients with HER2-negative, hormone receptor–positive advanced breast cancer

Clinical Cancer Research, ISSN: 15573265 10780432

Maura N. Dickler; Saura; Donald A. Richards; Ian E. Krop; Andrés Cervantes; Philippe L. Bedard; Manish R. Patel; Pusztai; Oliveira; Alison Cardenas; Na Cui; Tim Wilson; Thomas J. Stout; Michael C. Wei; Jerry Hsu; Baselga

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Nature Communications,

Jill Spoerke; Steven Gendreau; Walter; Jiaheng Qiu; Tim Wilson; Heidi Savage; Junko Aimi; Mika Derynck; Meng Chen; Iris Chan; Lukas Amler; Garret Hampton; Stephen Johnston; Ian E. Krop; Schmid; Mark Lackner

Genomic alterations associated with recurrence and TNBC subtype in high-risk early breast cancers

Molecular Cancer Research, ISSN: 15417786

Tim Wilson; Akshata R. Udyavar; Ching-Wei Chang; Jill Spoerke; Junko Aimi; Heidi Savage; Anneleen Daemen; O'Shaughnessy; Richard Bourgon; Mark Lackner

Genentech, Postdoctoral Fellow – 2011
Massachusetts General Hospital/Harvard Medical School, Postdoctoral Fellow – 2010
Queen’s University, Belfast, Postdoctoral Fellow – 2008
Queen’s University, Belfast, Ph.D. in Cancer Biology – 2005
University of Ulster, B.Sc. in Applied Biochemical Sciences – 2002